



Press Release



Montpellier, December 20th, 2014

STABILIZATION – MEDTECH'S IPO

Final amount of the capital increase and Communication on the terms of stabilization operations

Natixis and Oddo, leaders and joint bookrunners in Medtech new share issues, at the time of its admission to negotiations on the regulated NYSE Euronext market in Paris has informed the company that they have not applied the over-allotment option that Medtech had consented to. Consequently, the final amount of the capital increase is 20.000.007 €uros corresponding to 740.741 new share issues.

Furthermore, in compliance with Article 631-10 of the Financial Market Authority's General Regulations, Natixis, as a stabilizing agent on account of the banking syndicate, indicates that:

- It has performed stabilization operations on Medtech shares (Code ISIN : FR0010892950 - mnemonic code: ROSA) ;
- Stabilization began on November 28, 2013 ;
- The last stabilization operation was performed on December 18, 2013.

This document must not be published, distributed or broadcast directly or indirectly, to the United States of America, Canada, Australia or Japan.



Press Release



- Stabilization operations were carried out under the following conditions:

Date	Lowest price (in €)	Highest price (in €)
28/11/2013	25.45	26.75
29/11/2013	25.40	25.65
03/12/2013	26.60	26.80
04/12/2013	26.39	26.70
05/12/2013	26.30	26.50
09/12/2013	26.25	26.25
10/12/2013	26.15	26.15
11/12/2013	26.15	26.15
12/12/2013	25.90	26.00
13/12/2013	25.75	25.75
16/12/2013	25.50	25.50
17/12/2013	25.50	25.50
18/12/2013	25.50	25.50

This document must not be published, distributed or broadcast directly or indirectly to the United States of America, Canada, Australia or Japan



Press Release



Here-below are Medtech's shareholdings on a non-diluted basis following its admission to negotiations on the regulated NYSE Euronext stock market, Paris, November 27, 2013

Associate	Number of shares	Percentage capital voting rights
Bertin Nahum	735 040	30.77%
Fernand Badano	47 860	2.00%
FCPR Newfund 1	548 660	22.97%
Soridec	22 500	1.41%
Jeremie LR5	33 760	0.94%
MIDI CAPITAL	84 380	3.53%
Eric Briole	38 280	1.60%
Sub-total social mandatories	1 510 480	63.24%
Evelyne Nahum-Giraudet	1 920	0.08%
Charles-Antoine Morand	1 520	0.06%
Sub-total other shareholders	3 440	0.14%
Lucien Blondel	28 720	1.20%
Pierre Maillet	28 720	1.20%
Eric Tassel	76 560	3.21%
Sub-total employees	134 000	5.61%
Free-float*	740 741	31.01%
TOTAL	2 388 661	100%

*Including Bpifrance's participation

This document must not be published, distributed or broadcast directly or indirectly to the United States of America, Canada, Australia or Japan



Press Release



FINANCIAL INTERMEDIARIES

Leaders and Associated Bookrunners



AVAILABILITY OF THE LEAFLET

Copies of the leaflet mentioned by the AMF on November 15 2013 under the number 13-617 (**the «Leaflet»**), consisting of a basic document recorded on October 28, 2013 under the number I.13-048 (**«Basic Document»**) and a transaction note (including the summary of **the prospectus**), are available free of charge and upon simple request at Medtech SA - Parc de Bellegarde - Bât. A - 1 chemin de Borie - 34170 Castelnau Le Lez and may be consulted on the Financial Markets Authority (AMF) website (www.amf-france.org) and Medtech's website (www.medtech-bourse.com).

RISK FACTORS

Before making their investment decision, Investors are invited, to pay attention to the risks described in chapter 4 «Risk Factors » of the Basis Document recorded on October 28, 2013 under the number I.13-048, and Chapter 2 « Offer-related Risk Factors » in the transaction note mentioned by the AMF on November 15 2013 under the number 13-617.

This document must not be published, distributed or broadcast directly or indirectly to the United States of America, Canada, Australia or Japan



Press Release



For more information about financial transactions: www.medtech-bourse.com

About MEDTECH

MEDTECH, founded in 2002 by Bertin NAHUM and based near Montpellier, is the European specialist in design, development and marketing of innovative robotic-assistive devices for medico-surgical interventions, thus contributing to the implementation of safer, more efficient, less invasive treatment.

In 2006, MEDTECH sold the patent portfolio for its first robot, BRIGIT™, designed for knee surgery, to Zimmer Inc. (NYSE : ZMH).

In 2007, MEDTECH developed ROSA™ Brain, an innovative robotic device devoted to brain surgery, which has now been officially approved in Europe, the United States and Canada.

With the launch of its latest robot, ROSA™ Spine, MEDTECH has broadened its field of intervention with this new equipment for spinal surgery.

In 2013, MEDTECH received the «European Company of the Year » award in the «robotics neurosurgery » category from Frost & Sullivan.

CONTACT MEDTECH

Christelle Gesler
Financial & Corporate Director
Tel : +33 (0)4 67 10 77 40
Tel: +33 (0)6 87 70 74 67
c.gesler@medtechsurgical.com

CONTACT for INVESTORS

Corinne Puissant
Tel : +33 (0)1 53 67 36 57
cpuissant@actus.fr

PRESS CONTACT

Alexandra Prisa
Tel. : +33(0)1 53 67 35 79
aprisa@actus.fr